September 11, 2026

AbbVie Qulipta LUNA Menstrual Migraine Phase 3 Win, Telix Pixclara PDUFA, Corbus CANYON-1 Data Call Sept 14

AbbVie atogepant clears LUNA Phase 3 menstrual migraine, Telix Pixclara PDUFA hits Sept 11, Corbus CANYON-1 topline data call set for Sept 14.

6 stories · Covering clinical-trials, regulatory, industry

Editor's Note

Friday closed the Wells Fargo Healthcare Conference week and delivered three specific readouts alongside quieter follow-on coverage from the earlier ERS and ESPE meetings. AbbVie's Qulipta (atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist small molecule already approved for episodic and chronic migraine) met the primary and all eight ranked secondary endpoints of the Phase 3 LUNA trial in menstrual migraine, positioning atogepant as the first potential FDA-approved therapy specifically for the perimenstrual migraine window. Telix Pharmaceuticals' PDUFA action date for Pixclara (floretyrosine F 18), a PET imaging agent for characterizing recurrent or progressive glioma versus treatment-related changes, arrived Friday September 11 — the drug carries FDA Fast Track and Orphan Drug designations. Corbus Pharmaceuticals scheduled the CANYON-1 Phase 1b topline conference call for Monday September 14 at 8:00 a.m. ET, ending the September-window countdown for the CRB-913 peripherally-restricted CB1 inverse agonist obesity data. Ionis Pharmaceuticals used its Wells Fargo fireside chat to disclose that TRYNGALZA (olezarsen) reached $32 million in H1 2026 U.S. sales with $100-110 million full-year guidance and $2 billion peak sales guidance in the newly-launched severe hypertriglyceridemia indication. Roivant analyst upgrades continued mid-week, with TD Cowen lifting to $55 (from $50) and Jefferies to $52 (from $42) following Tuesday's Phase 2 PHocus mosliciguat win. On the oral GLP-1 launch tracker, Novo Nordisk's Wegovy pill hit an approximate 183,000 weekly total scripts per IQVIA data — its highest weekly total since the January 2026 U.S. launch.

Clinical Trials

AbbVie Qulipta (Atogepant) Meets Primary and All Eight Secondary Endpoints of Phase 3 LUNA Trial in Menstrual Migraine; First Potential FDA-Approved Therapy Specifically for Perimenstrual Migraine

AbbVie (NYSE: ABBV) announced Friday September 11, 2026 positive topline results from the Phase 3 LUNA trial evaluating Qulipta (atogepant, an oral calcitonin gene-related peptide receptor antagonist small molecule) for the preventive treatment of menstrual migraine in adults. LUNA is a multicenter randomized double-blind placebo-controlled trial that enrolled 468 adult women with pure menstrual migraine or menstrually-related migraine across sites in Europe and Asia; participants took atogepant for 7 consecutive days starting 3 days before the onset of menses, repeated over 3 menstrual cycles. Atogepant reduced perimenstrual migraine days by a mean of 1.20 days versus 0.40 days with placebo (0.80 fewer migraine days versus placebo, p<0.0001) and met all 8 ranked secondary endpoints (p<0.0001). No treatment is currently FDA-approved specifically for menstrual migraine. AbbVie plans to submit the LUNA data to health authorities and present at future medical congresses. Qulipta is already approved in the U.S. for adults with episodic migraine and chronic migraine — the LUNA readout supports a distinct short-term perimenstrual dosing regimen and potentially a dedicated label expansion. CGRP is a neuropeptide involved in migraine pathophysiology; atogepant is a small-molecule CGRP receptor antagonist rather than a peptide itself.

#abbvie #abbv #qulipta #atogepant #luna-phase-3 #menstrual-migraine #perimenstrual-migraine #cgrp-receptor-antagonist #468-adult-women #primary-endpoint-met #8-secondary-endpoints #first-approved-therapy-menstrual-migraine #existing-migraine-indications #cgrp-neuropeptide-target #non-peptide-small-molecule

Regulatory

Telix Pharmaceuticals Pixclara (Floretyrosine F 18) FDA PDUFA Action Date Arrives Friday September 11 for PET Imaging of Recurrent or Progressive Glioma

Telix Pharmaceuticals Limited (NASDAQ: TLX) reached its FDA Prescription Drug User Fee Act (PDUFA) action date of Friday September 11, 2026 for TLX101-Px (Pixclara, floretyrosine F 18, also called 18F-FET), an investigational positron emission tomography (PET) imaging agent designed to help distinguish recurrent or progressive glioma from treatment-related changes in adult and pediatric patients with previously treated glioma. The FDA had accepted the resubmitted NDA in April 2026 following an earlier complete response letter. Pixclara carries FDA Fast Track and Orphan Drug designations. Standard MRI post-treatment surveillance struggles to differentiate true tumor progression from pseudoprogression or radiation necrosis; a PET imaging agent that binds selectively to actively metabolizing tumor cells addresses a substantial diagnostic gap. If approved, Pixclara would be one of the first tumor-specific glioma PET agents to enter the U.S. market. The company had not confirmed the FDA action outcome as of end of Friday U.S. business hours; investors were watching for a Monday morning announcement.

#telix-pharmaceuticals #tlx #pixclara #tlx101-px #floretyrosine-f-18 #18f-fet #pdufa-september-11 #pet-imaging-agent #glioma-imaging #recurrent-progressive-glioma #fast-track-designation #orphan-drug-designation #post-treatment-surveillance #non-peptide

Clinical Trials

Corbus Pharmaceuticals Sets Monday September 14 Conference Call for CANYON-1 Phase 1b Topline Data on CRB-913 Peripherally-Restricted CB1 Inverse Agonist for Obesity

Corbus Pharmaceuticals (NASDAQ: CRBP) announced Friday September 11, 2026 that the company will host a conference call and webcast Monday September 14 at 8:00 a.m. EDT to discuss topline data from the Phase 1b CANYON-1 trial of CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up (NCT07310901). Last patient last visit was reported August 4, 2026. Harold Bays MD (investigator) will join the call as a guest speaker. CRB-913 is designed to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve weight-loss efficacy while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). The Monday readout is one of the most-watched non-incretin obesity data points on the September calendar. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as a differentiated add-on or alternative to the GLP-1 class.

#corbus-pharmaceuticals #crbp #crb-913 #canyon-1 #phase-1b-topline-monday #september-14-conference-call #peripherally-restricted-cb1-inverse-agonist #240-participants #16-week-study #monlunabant-comparator #rimonabant-history #harold-bays-investigator #obesity #non-peptide

Industry

Ionis Pharmaceuticals Updates on TRYNGALZA (Olezarsen) Wells Fargo Launch Metrics: $32 Million H1 2026 U.S. Sales, $100-110 Million Full-Year 2026 Guidance, $2 Billion Peak Sales Guidance in Severe Hypertriglyceridemia

Ionis Pharmaceuticals (NASDAQ: IONS) CEO Brett Monia participated in a fireside chat Thursday September 10, 2026 at the Wells Fargo 21st Annual Healthcare Conference in Boston, disclosing TRYNGALZA (olezarsen, an antisense oligonucleotide that reduces apolipoprotein C-III production and lowers triglycerides) H1 2026 U.S. net product sales of $32 million (Q2 alone was $5 million) with full-year 2026 guidance of $100-110 million. The severe hypertriglyceridemia (sHTG) launch followed June 2026 FDA approval and represents the first indication expansion from the initial familial chylomicronemia syndrome (FCS) indication. Ionis raised peak sales guidance in the sHTG indication from $1 billion-plus to $2 billion-plus. The sHTG marketing application is under review in the European Union with potential launch in 2027. Ionis is also commercializing the September 3, 2026 FDA-approved ZANVASTRO (zilganersen, an antisense oligonucleotide) for Alexander disease, a first-in-class disease-modifying therapy for a rare progressive neurodegenerative disorder with no other approved therapies. The company acknowledged parallel setbacks in cardiovascular studies including the Novartis pelacarsen Phase 3 Lp(a)HORIZON miss reported September 4.

#ionis-pharmaceuticals #ions #tryngalza #olezarsen #antisense-oligonucleotide #severe-hypertriglyceridemia #shtg-indication #familial-chylomicronemia-syndrome #fcs #32-million-h1-sales #100-110-million-fy-guidance #2-billion-peak-sales #brett-monia-ceo #wells-fargo-2026-conference #zanvastro-second-launch #pelacarsen-setback

Industry

Roivant Analyst Price Targets Continue Rising Through Mid-Week Following Pulmovant PHocus Phase 2 Win: TD Cowen to $55 (From $50), Jefferies to $52 (From $42)

Sell-side analyst upgrades on Roivant Sciences (NASDAQ: ROIV) continued through Wednesday-Thursday September 9-10, 2026 following the Tuesday September 8 Pulmovant Phase 2 PHocus win in pulmonary hypertension associated with interstitial lung disease. TD Cowen raised its ROIV price target to $55 from $50 with a Buy rating; Jefferies raised to $52 from $42 with a Buy rating. These upgrades follow the Guggenheim ($46 from $42) and Piper Sandler ($55 from $40) targets published Wednesday September 9. Guggenheim estimated peak sales of approximately $3 billion in PH-ILD. Consensus analyst estimates now cluster around a $50-55 target range. The PHocus study achieved a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 (p<0.0001) with placebo-adjusted improvements of +35.2 meters six-minute walk distance and −53.2% NT-proBNP from baseline. The Phase 3 PHrontier study is enrolling approximately 375 patients globally in a 1:1 randomized double-blind placebo-controlled design.

#roivant-sciences #roiv #pulmovant #mosliciguat #phocus-trial #td-cowen-55-target #jefferies-52-target #guggenheim-46-target #piper-sandler-55-target #50-to-55-consensus-range #3-billion-peak-sales #ph-ild #phrontier-phase-3 #375-patients #non-peptide

Industry

Oral GLP-1 Weekly Prescription Tracker Hits New High: Novo Wegovy Pill Reaches Approximately 183,000 Weekly Total Scripts Per IQVIA Data

The oral GLP-1 launch race entered its ninth month with Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg for chronic weight management, U.S. launch January 5, 2026) reaching approximately 183,000 weekly total scripts per the most recent IQVIA week ending September 5, 2026 — the highest weekly total since launch. Eli Lilly's Foundayo (orforglipron, once-daily oral small-molecule non-peptide GLP-1 receptor agonist, U.S. launch April 2026) continued its own prescription climb through the same reporting window. Both products are indicated for adults with obesity or overweight with weight-related comorbidities. Wegovy pill's climb reflects continued Medicare Part D coverage expansion following the November 2025 pricing agreement (Ozempic Pill / Wegovy pill at $149/month per the deal) and CMS 2026 formulary guidance. Foundayo pricing on TrumpRx and cash-pay LillyDirect anchors at $149/month at starting doses. The concurrent oral launch trajectories are the largest test to date of oral incretin adoption relative to the established weekly-injectable class dominated by injectable Wegovy and Zepbound.

#wegovy-pill #oral-semaglutide-25-50-mg #novo-nordisk #nvo #foundayo #orforglipron #eli-lilly #lly #iqvia-weekly-tracker #183000-weekly-scripts #oral-glp-1-launch-race #trumprx-149-month #medicare-part-d-expansion #glp-1